Pharmacologic Treatment of Intractable Epilepsy in Children: A Syndrome-Based Approach

Seminars in Pediatric Neurology

Volumn 18, Issue 3, 2011, Pages 171-178

  Hussain, Shaun ^a   Sankar, Raman ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CORTICOTROPIN; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; IMMUNOGLOBULIN; LAMOTRIGINE; METHYLPREDNISOLONE; MIDAZOLAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREDNISOLONE; PREDNISONE; RUFINAMIDE; SODIUM CHANNEL NAV1.1; STIRIPENTOL; SULTIAME; TETRACOSACTIDE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; ADJUVANT THERAPY; AGGRESSION; ATTENTION DISTURBANCE; BEDTIME DOSAGE; BENIGN CHILDHOOD EPILEPSY; BENIGN EPILEPSY WITH CENTROTEMPORAL SPIKES; CHILD; CONTINUOUS INFUSION; DRUG CHOICE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DYSLEXIA; EPILEPTIC STATE; FEBRILE CONVULSION; FLUENCY DISORDER; FOCAL EPILEPSY; HUMAN; INFANTILE SPASM; INTRACTABLE EPILEPSY; IRRITABILITY; LANDAU KLEFFNER SYNDROME; LENNOX GASTAUT SYNDROME; LOW DRUG DOSE; MEMORY DISORDER; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; NEUTROPENIA; NEWBORN SEIZURE; NONHUMAN; REVIEW; SEDATION; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIDE EFFECT; SLOW WAVE SLEEP; STEVENS JOHNSON SYNDROME; TONIC CLONIC SEIZURE; TUBEROUS SCLEROSIS; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WORKING MEMORY;

ANTICONVULSANTS; EPILEPSY; HUMANS; PEDIATRICS;

EID: 80655145948     PISSN: 10719091     EISSN: 15580776     Source Type: Journal    
DOI: 10.1016/j.spen.2011.06.003     Document Type: Review

References (155)

1. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
2. Kwan P., Brodie M.J. Effectiveness of first antiepileptic drug. Epilepsia 2001, 42:1255-1260.
3. Benbadis S.R., Tatum W.O., Gieron M. Idiopathic generalized epilepsy and choice of antiepileptic drugs. Neurology 2003, 61:1793-1795.
4. Painter M.J., Scher M.S., Stein A.D., et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med 1999, 341:485-489.
5. Bittigau P., Sifringer M., Genz K., et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci U S A 2002, 99:15089-15094.
6. Silverstein F.S., Ferriero D.M. Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol 2008, 39:77-79.
7. Shoemaker M.T., Rotenberg J.S. Levetiracetam for the treatment of neonatal seizures. J Child Neurol 2007, 22:95-98.
8. Fürwentsches A., Bussmann C., Ramantani G., et al. Levetiracetam in the treatment of neonatal seizures: A pilot study. Seizure 2010, 19:185-189.
9. Ramantani G., Ikonomidou C., Walter B., et al. Levetiracetam: Safety and efficacy in neonatal seizures. Eur J Paediatr Neurol 2011, 15:1-7.
10. Abend N.S., Gutierrez-Colina A.M., Monk H.M., et al. Levetiracetam for treatment of neonatal seizures. J Child Neurol 2011, 26:465-470.
11. Khan O., Chang E., Cipriani C., et al. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol 2011, 44:265-269.
12. Manthey D., Asimiadou S., Stefovska V., et al. Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp Neurol 2005, 193:497-503.
13. Kim J.-S., Kondratyev A., Tomita Y., et al. Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. Epilepsia 2007, 48(suppl 5):19-26.
14. Koh S., Tibayan F.D., Simpson J.N., et al. NBQX or topiramate treatment after perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury. Epilepsia 2004, 45:569-575.
15. Schubert S., Brandl U., Brodhun M., et al. Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets. Brain Res 2005, 1058:129-136.
16. Sfaello I., Baud O., Arzimanoglou A., et al. Topiramate prevents excitotoxic damage in the newborn rodent brain. Neurobiol Dis 2005, 20:837-848.
17. Follett P.L., Deng W., Dai W., et al. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: A protective role for topiramate. J Neurosci 2004, 24:4412-4420.
18. Wolf S.M., Carr A., Davis D.C., et al. The value of phenobarbital in the child who has had a single febrile seizure: A controlled prospective study. Pediatrics 1977, 59:378-385.
19. Farwell J.R., Lee Y.J., Hirtz D.G., et al. Phenobarbital for febrile seizures-Effects on intelligence and on seizure recurrence. N Engl J Med 1990, 322:364-369.
20. Febrile seizures: Clinical practice guideline for the long-term management of the child with simple febrile seizures. Pediatrics 2008, 121:1281-1286. Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics.
21. Shinnar S., Berg A.T., Moshe S.L., et al. How long do new-onset seizures in children last?. Ann Neurol 2001, 49:659-664.
22. Sankar R. Initial treatment of epilepsy with antiepileptic drugs: Pediatric issues. Neurology 2004, 63:S30-S39.
23. Mackay M.T., Weiss S.K., Adams-Webber T., et al. Practice parameter: Medical treatment of infantile spasms: Report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004, 62:1668-1681.
24. Baram T.Z., Mitchell W.G., Tournay A., et al. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: A prospective, randomized, blinded study. Pediatrics 1996, 97:375-379.
25. Elterman R.D., Shields W.D., Bittman R.M., et al. Vigabatrin for the treatment of infantile spasms: Final report of a randomized trial. J Child Neurol 2010, 25:1340-1347.
26. Lerner J.T., Salamon N., Sankar R. Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms. Neuropsychiatr Dis Treat 2010, 6:731-740.
27. Yanai S., Hanai T., Narazaki O. Treatment of infantile spasms with zonisamide. Brain Dev 1999, 21:157-161.
28. Suzuki Y., Imai K., Toribe Y., et al. Long-term response to zonisamide in patients with West syndrome. Neurology 2002, 58:1556-1559.
29. Lotze T.E., Wilfong A.A. Zonisamide treatment for symptomatic infantile spasms. Neurology 2004, 62:296-298.
30. Yanagaki S., Oguni H., Yoshii K., et al. Zonisamide for West syndrome: A comparison of clinical responses among different titration rate. Brain Dev 2005, 27:286-290.
31. Yum M.-S., Ko T.-S. Zonisamide in West syndrome: An open label study. Epileptic Disord 2009, 11:339-344.
32. Glauser T.A., Clark P.O., Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998, 39:1324-1328.
33. Hosain S.A., Merchant S., Solomon G.E., et al. Topiramate for the treatment of infantile spasms. J Child Neurol 2006, 21:17-19.
34. Kwon Y.-S., Jun Y.-H., Hong Y.-J., et al. Topiramate monotherapy in infantile spasm. Yonsei Med J 2006, 47:498-504.
35. Dyken P.R., DuRant R.H., Minden D.B., et al. Short term effects of valproate on infantile spasms. Pediatr Neurol 1985, 1:34-37.
36. Hrachovy R.A., Frost J.D., Kellaway P., et al. Double-blind study of ACTH vs prednisone therapy in infantile spasms. J Pediatr 1983, 103:641-645.
37. Lux A.L., Edwards S.W., Hancock E., et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: A multicentre, randomised controlled trial. Lancet 2004, 364:1773-1778.
38. Kossoff E.H., Hartman A.L., Rubenstein J.E., et al. High-dose oral prednisolone for infantile spasms: An effective and less expensive alternative to ACTH. Epilepsy Behav 2009, 14:674-676.
39. Kurokawa T., Goya N., Fukuyama Y., et al. West syndrome and Lennox-Gastaut syndrome: A survey of natural history. Pediatrics 1980, 65:81-88.
40. Ohtahara S. Seizure disorders in infancy and childhood. Brain Dev 1984, 6:509-519.
41. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome. N Engl J Med 1993, 328:29-33.
42. Donaldson J.A., Glauser T.A., Olberding L.S. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut syndrome). Epilepsia 1997, 38:68-73.
43. Motte J., Trevathan E., Arvidsson J.F., et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997, 337:1807-1812.
44. Sachdeo R.C., Glauser T.A., Ritter F., et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999, 52:1882-1887.
45. Glauser T.A., Levisohn P.M., Ritter F., et al. Topiramate in Lennox-Gastaut syndrome: Open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000, 41(suppl 1):S86-S90.
46. Guerrini R., Belmonte A., Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998, 39(suppl 3):S2-S10.
47. Guerrini R., Dravet C., Genton P., et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998, 39:508-512.
48. Janszky J., Rásonyi G., Halász P., et al. Disabling erratic myoclonus during lamotrigine therapy with high serum level-Report of two cases. Clin Neuropharmacol 2000, 23:86-89.
49. Stephen L.J., Sills G.J., Brodie M.J. Lamotrigine and topiramate may be a useful combination. Lancet 1998, 351:958-959.
50. Glauser T., Kluger G., Sachdeo R., et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008, 70:1950-1958.
51. Kluger G., Glauser T., Krauss G., et al. Adjunctive Rufinamide in Lennox-Gastaut syndrome: A long-term, open-label extension study. Acta Neurol Scand 2010, 122:202-208.
52. Wheless J.W., Vazquez B. Rufinamide: A novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010, 10:1-6.
53. Conry J.A., Ng Y.-T., Paolicchi J.M., et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009, 50:1158-1166.
54. Harkin L.A., McMahon J.M., Iona X., et al. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 2007, 130:843-852.
55. Escayg A., MacDonald B.T., Meisler M.H., et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet 2000, 24:343-345.
56. Wallace R.H., Scheffer I.E., Barnett S., et al. Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus. Am J Hum Genet 2001, 68:859-865.
57. Ebach K., Joos H., Doose H., et al. SCN1A mutation analysis in myoclonic astatic epilepsy and severe idiopathic generalized epilepsy of infancy with generalized tonic-clonic seizures. Neuropediatrics 2005, 36:210-213.
58. Wallace R.H., Hodgson B.L., Grinton B.E., et al. Sodium channel alpha1-subunit mutations in severe myoclonic epilepsy of infancy and infantile spasms. Neurology 2003, 61:765-769.
59. Ohmori I., Ouchida M., Kobayashi K., et al. Rasmussen encephalitis associated with SCN 1 A mutation. Epilepsia 2008, 49:521-526.
60. Grosso S., Orrico A., Galli L., et al. SCN1A mutation associated with atypical Panayiotopoulos syndrome. Neurology 2007, 69:609-611.
61. Gambardella A., Marini C. Clinical spectrum of SCN1A mutations. Epilepsia 2009, 50(suppl 5):20-23.
62. Yu F.H., Mantegazza M., Westenbroek R.E., et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006, 9:1142-1149.
63. Thanh T.N., Chiron C., Dellatolas G., et al. Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet's syndrome). Arch Pediatr 2002, 9:1120-1127.
64. Perez J., Chiron C., Musial C., et al. Stiripentol: Efficacy and tolerability in children with epilepsy. Epilepsia 1999, 40:1618-1626.
65. Chiron C., Marchand M.C., Tran A., et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000, 356:1638-1642.
66. Nieto-Barrera M., Candau R., Nieto-Jimenez M., et al. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000, 9:590-594.
67. Coppola G., Capovilla G., Montagnini A., et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: An Italian multicenter open trial. Epilepsy Res 2002, 49:45-48.
68. Kröll-Seger J., Portilla P., Dulac O., et al. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics 2006, 37:325-329.
69. Tassinari C.A., Rubboli G., Volpi L., et al. Encephalopathy with electrical status epilepticus during slow sleep or ESES syndrome including the acquired aphasia. Clin Neurophysiol 2000, 111(suppl 2):S94-S102.
70. Van Hirtum-Das M., Licht E.A., Koh S., et al. Children with ESES: Variability in the syndrome. Epilepsy Res 2006, 70(suppl 1):S248-S258.
71. De Negri M., Baglietto M.G., Battaglia F.M., et al. Treatment of electrical status epilepticus by short diazepam (DZP) cycles after DZP rectal bolus test. Brain Dev 1995, 17:330-333.
72. Riviello J.J., Holder D.L., Thiele E., et al. Treatment of continuous spikes and waves during slow-wave sleep with high-dose diazepam. Epilepsia 2001, 42(abstr):56.
73. Kramer U., Sagi L., Goldberg-Stern H., et al. Clinical spectrum and medical treatment of children with electrical status epilepticus in sleep (ESES). Epilepsia 2009, 50:1517-1524.
74. Marescaux C., Hirsch E., Finck S., et al. Landau-Kleffner syndrome: A pharmacologic study of five cases. Epilepsia 1990, 31:768-777.
75. Holmes G.L., Riviello J.J. Treatment of childhood idiopathic language deterioration with valproate. Epilepsy Behav 2001, 2:272-276.
76. Inutsuka M., Kobayashi K., Oka M., et al. Treatment of epilepsy with electrical status epilepticus during slow sleep and its related disorders. Brain Dev 2006, 28:281-286.
77. Rossi P.G., Parmeggiani A., Posar A., et al. Landau-Kleffner syndrome (LKS): Long-term follow-up and links with electrical status epilepticus during sleep (ESES). Brain Dev 1999, 21:90-98.
78. Kossoff E.H., Boatman D., Freeman J.M. Landau-Kleffner syndrome responsive to levetiracetam. Epilepsy Behav 2003, 4:571-575.
79. Capovilla G., Beccaria F., Cagdas S., et al. Efficacy of levetiracetam in pharmacoresistant continuous spikes and waves during slow sleep. Acta Neurol Scand 2004, 110:144-147.
80. Aeby A., Poznanski N., Verheulpen D., et al. Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: Experience in 12 cases. Epilepsia 2005, 46:1937-1942.
81. Boel M., Casaer P. Continuous spikes and waves during slow sleep: A 30 months follow-up study of neuropsychological recovery and EEG findings. Neuropediatrics 1989, 20:176-180.
82. Guerreiro M.M., Camargo E.E., Kato M., et al. Brain single photon emission computed tomography imaging in Landau-Kleffner syndrome. Epilepsia 1996, 37:60-67.
83. Tsuru T., Mori M., Mizuguchi M., et al. Effects of high-dose intravenous corticosteroid therapy in Landau-Kleffner syndrome. Pediatr Neurol 2000, 22:145-147.
84. Sinclair D.B., Snyder T.J. Corticosteroids for the treatment of Landau-Kleffner syndrome and continuous spike-wave discharge during sleep. Pediatr Neurol 2005, 32:300-306.
85. Buzatu M., Christine, Altuzarra C., et al. Bulteau undefined céciliae Altuzarra undefined Olivier Dulac undefined, and undefined Patrick Van Bogaert. Corticosteroids as treatment of epileptic syndromes with continuous spike-waves during slow-wave sleep. Epilepsia 2009, 50:68-72.
86. Aykut-Bingol C., Arman A. Pulse methylprednisolone therapy in Landau-Kleffner syndrome. J Epilepsy 1996, 9:189-191.
87. Lerman P., Lerman-Sagie T., Kivity S. Effect of early corticosteroid therapy for Landau-Kleffner syndrome. Dev Med Child Neurol 1991, 33:257-260.
88. Perniola T., Margari L., Buttiglione M., et al. A case of Landau-Kleffner syndrome secondary to inflammatory demyelinating disease. Epilepsia 1993, 34:551-556.
89. Tütüncüoǧlu S., Serdaroǧlu G., Kadioǧlu B. Landau-Kleffner syndrome beginning with stuttering: Case report. J Child Neurol 2002, 17:785-788.
90. Fayad M.N., Choueiri R., Mikati M. Landau-Kleffner syndrome: Consistent response to repeated intravenous gamma-globulin doses: A case report. Epilepsia 1997, 38:489-494.
91. Lagae L.G., Silberstein J., Gillis P.L., et al. Successful use of intravenous immunoglobulins in Landau-Kleffner syndrome. Pediatr Neurol 1998, 18:165-168.
92. Mikati M.A., Shamseddine A.N. Management of Landau-Kleffner syndrome. Paediatr Drugs 2005, 7:377-389.
93. Arts W.F.M., Femke K. Aarsen undefined Marjan Scheltens-de Boer undefined, and undefined Coriene E Catsman-Berrevoets. Landau-Kleffner syndrome and CSWS syndrome: Treatment with intravenous immunoglobulins. Epilepsia 2009, 50:55-58.
94. Shields W.D., Lake J.L., Chugani H.T. Amantadine in the treatment of refractory epilepsy in childhood: An open trial in 10 patients. Neurology 1985, 35:579-581.
95. Shahar E.M., Brand N. Effect of add-on amantadine therapy for refractory absence epilepsy. J Pediatr 1992, 121:819-821.
96. Shields W.D., Snead O.C. Benign epilepsy with centrotemporal spikes. Epilepsia 2009, 50(suppl 8):10-15.
97. Rating D., Wolf C., Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: A 6-month randomized, double-blind, placebo-controlled study. Epilepsia 2000, 41:1284-1288.
98. Bast T., Völp A., Wolf C., et al. The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS). Epilepsia 2003, 44:215-220.
99. Wirrell E., Sherman E.M.S., Vanmastrigt R., et al. Deterioration in cognitive function in children with benign epilepsy of childhood with central temporal spikes treated with sulthiame. J Child Neurol 2008, 23:14-21.
100. Bourgeois B.F., Brown L.W., Pellock J.M. Gabapentin monotherapy in children with benign childhood epilepsy with centrotemporal spikes (BECTS): A 36 week, double-blind, placebo-controlled study. Epilepsia 1998, 39(suppl 6, abstr):163.
101. Jallon P., Picard F. Body weight gain and anticonvulsants: A comparative review. Drug Saf 2001, 24:969-978.
102. Seidel W.T., Mitchell W.G. Cognitive and behavioral effects of carbamazepine in children: Data from benign rolandic epilepsy. J Child Neurol 1999, 14:716-723.
103. Coppola G., Franzoni E., Verrotti A., et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): An open-label, parallel group trial. Brain Dev 2007, 29:281-284.
104. Zimmerman F.T., Burgemeister B.B. A new drug for petit mal epilepsy. Neurology 1958, 8:769-775.
105. Chao D.H., Plumb R.L. Diamox in epilepsy. A critical review of 178 cases. J Pediatr 1961, 58:211-218.
106. Lombroso C.T., Forxythe I. A long-term follow-up of acetazolamide (Diamox) in the treatment of epilepsy. Epilepsia 1960, 1:493-500.
107. Villarreal H.J., Wilder B.J., Willmore L.J., et al. Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology 1978, 28:886-891.
108. Rowan A.J., Meijer J.W., de Beer-Pawlikowski N., et al. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983, 40:797-802.
109. Santavuori P. Absence seizures: Valproate or ethosuximide?. Acta Neurol Scand Suppl 1983, 97:41-48.
110. Mattson R.H., Cramer J.A. Valproic acid and ethosuximide interaction. Ann Neurol 1980, 7:583-584.
111. Frank L.M., Enlow T., Holmes G.L., et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999, 40:973-979.
112. Buoni S., Grosso S., Fois A. Lamotrigine in typical absence epilepsy. Brain Dev 1999, 21:303-306.
113. Holmes G.L., Frank L.M., Sheth R.D., et al. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res 2008, 82:124-132.
114. Glauser T.A., Cnaan A., Shinnar S., et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010, 362:790-799.
115. Gower A.J., Hirsch E., Boehrer A., et al. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 1995, 22:207-213.
116. Gallagher M.J., Eisenman L.N., Brown K.M., et al. Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy. Epilepsia 2004, 45:90-91.
117. Fattore C., Boniver C., Capovilla G., et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia 2011, 52:802-809.
118. Perucca E., Gram L., Avanzini G., et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998, 39:5-17.
119. Snead O.C., Hosey L.C. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985, 313:916-921.
120. Wirrell E.C., Camfield C.S., Camfield P.R., et al. Long-term prognosis of typical childhood absence epilepsy: Remission or progression to juvenile myoclonic epilepsy. Neurology 1996, 47:912-918.
121. Durner M., Keddache M.A., Tomasini L., et al. Genome scan of idiopathic generalized epilepsy: Evidence for major susceptibility gene and modifying genes influencing the seizure type. Ann Neurol 2001, 49:328-335.
122. Penry J.K., Dean J.C., Riela A.R. Juvenile myoclonic epilepsy: Long-term response to therapy. Epilepsia 1989, 30(suppl 4):S19-S23.
123. Calleja S., Salas-Puig J., Ribacoba R., et al. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate. Seizure 2001, 10:424-427.
124. Prasad A., Kuzniecky R.I., Knowlton R.C., et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2003, 60:1100-1105.
125. Guerrini R., Belmonte A., Parmeggiani L., et al. Myoclonic status epilepticus following high-dosage lamotrigine therapy. Brain Dev 1999, 21:420-424.
126. Specchio L.M., Gambardella A., Giallonardo A.T., et al. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res 2006, 71:32-39.
127. Noachtar S., Andermann E., Meyvisch P., et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008, 70:607-616.
128. Rosenfeld W.E., Benbadis S., Edrich P., et al. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: Analysis of two randomized, double-blind, placebo-controlled studies. Epilepsy Res 2009, 85:72-80.
129. Verity C.M., Hosking G., Easter D.J. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The Paediatric EPITEG Collaborative Group. Dev Med Child Neurol 1995, 37:97-108.
130. de Silva M., MacArdle B., McGowan M., et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996, 347:709-713.
131. Guerreiro M.M., Vigonius U., Pohlmann H., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997, 27:205-213.
132. Biton V., Montouris G.D., Ritter F., et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999, 52:1330-1337. Topiramate YTC Study Group.
133. Montouris G.D., Biton V., Rosenfeld W.E. Nonfocal generalized tonic-clonic seizures: Response during long-term topiramate treatment. Topiramate YTC/YTCE Study Group. Epilepsia 2000, 41(suppl 1):S77-S81.
134. Wheless J.W., Neto W., Wang S., et al. Topiramate, carbamazepine, and valproate monotherapy: Double-blind comparison in children with newly diagnosed epilepsy. J Child Neurol 2004, 19:135-141.
135. Biton V., Sackellares J.C., Vuong A., et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005, 65:1737-1743.
136. Trevathan E., Kerls S.P., Hammer A.E., et al. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Pediatrics 2006, 118:e371-e378.
137. Crompton D.E., Scheffer I.E., Taylor I., et al. Familial mesial temporal lobe epilepsy: A benign epilepsy syndrome showing complex inheritance. Brain 2010, 133:3221-3231.
138. Wheless J.W., Clarke D.F., Carpenter D. Treatment of pediatric epilepsy: Expert opinion. J Child Neurol 2005, 20(suppl 1):S1-S56.
139. Villanueva V., Sánchez-Álvarez J.C., Peña P., et al. Treatment initiation in epilepsy: An expert consensus in Spain. Epilepsy Behav 2010, 19:332-342.
140. Shinnar S., Pellock J.M., Conry J.A. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol 2009, 13:3-9.
141. Glauser T.A., Dlugos D.J., Dodson W.E., et al. Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents. J Child Neurol 2007, 22:693-699.
142. Mockenhaupt M., Messenheimer J., Tennis P., et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005, 64:1134-1138.
143. Guberman A.H., Besag F.M.C., Brodie M.J., et al. Lamotrigine-associated rash: Risk/benefit considerations in adults and children. Epilepsia 1999, 40:985-991.
144. Messenheimer J.A., Guberman A.H. Rash with lamotrigine: Dosing guidelines. Epilepsia 2000, 41:488.
145. Lee Y.J., Kang H.-C., Kim H.D., et al. Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy. Pediatr Neurol 2010, 42:86-92.
146. Kossoff E.H., Bergey G.K., Freeman J.M., et al. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001, 42:1611-1613.
147. Dinkelacker V., Dietl T., Widman G., et al. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: Report of 33 mild to severe cases. Epilepsy Behav 2003, 4:537-547.
148. Levisohn P.M., Mintz M., Hunter S.J., et al. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: A randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia 2009, 50:2377-2389.
149. Major P., Greenberg E., Khan A., et al. Pyridoxine supplementation for the treatment of levetiracetam-induced behavior side effects in children: Preliminary results. Epilepsy Behav 2008, 13:557-559.
150. Davis G.P., McCarthy J.T., Magill D.B., et al. Behavioral effects of levetiracetam mitigated by pyridoxine. J Child Adolesc Psychopharmacol 2009, 19:209-211.
151. Lee S., Szujkas V., Andermann F., et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003, 44:339-347.
152. Kochelmann E., Elger C.E., Helmstaedter C. Significant improvement in frontal lobe assocaited neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res 2003, 54:171-178.
153. Gross-Tsur V., Shalev R.S. Reversible language regression as an adverse effect of topiramate treatment in children. Neurology 2004, 62:299-300.
154. Chung S., Sperling M.R., Biton V., et al. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia 2010, 51:958-967.
155. Errington A.C., Stöhr T., Heers C., et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008, 73:157-169.